Two separate studies have identified changes in T-cell subsets before and after treatment with the anti-PD-1 antibody, pembrolizumab (Keytruda), that are predictive of treatment response, new research indicated.
MRV Research
GM-CSF Failed to Improve Survival in Resected Late-Stage Melanoma
Neither granulocyte-macrophage colony-stimulating factor (GM-CSF) nor peptide vaccination (PV), both thought to contribute to antitumor responses, significantly improved survival outcomes in patients with high-risk resected melanoma, according to the results of a phase III study.
Local administration of CpG-B prolongs RFS in early-stage melanoma
Patients with stage I or stage II melanoma who received the immune system-boosting agent CpG-B appeared less likely to experience disease recurrence than patients who received placebo, according to study results presented at the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York.
Preventing benign moles from turning cancerous
Human moles are generally similar in size, color, and shape. Usually absent at birth, they start out as tiny little dots that grow slowly for one to two years to a few millimeters, about the size of a pencil eraser, and then stop. The cells don’t die; they just exist.